Related Experiment Video

Updated: Mar 6, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.3K

Advances and challenges in targeting FGFR signalling in cancer

Irina S Babina1, Nicholas C Turner1,2

  • 1Breast Cancer Now Research Centre, Institute of Cancer Research, London SW3 6JB, UK.

Nature Reviews. Cancer
|March 18, 2017
PubMed

Insights

Fibroblast growth factor receptors (FGFRs) are key in cancer, but targeting them has yielded mixed clinical results. Understanding diverse FGFR activation mechanisms is crucial for effective cancer therapy response and resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Fibroblast growth factors (FGFs) and their receptors (FGFRs) are vital regulators of cellular functions.
  • Aberrant FGFR signaling is implicated in various cancers, presenting a therapeutic target.
  • Preclinical data supports FGFRs as promising cancer targets.

Purpose of the Study:

  • To review the diverse mechanisms of oncogenic FGFR activation.
  • To explore factors influencing response and resistance to FGFR-targeted therapies.
  • To highlight the complexities in targeting FGFR signaling in cancer.

Main Methods:

  • Literature review of preclinical and clinical studies on FGFR signaling in cancer.
  • Analysis of diverse mechanisms driving FGFR oncogenic activation.
  • Examination of resistance and response determinants in FGFR-targeted therapies.

Main Results:

  • FGFR signaling deregulation is a common feature in a subset of cancers.
  • Early clinical trials for FGFR-targeted therapies show varied outcomes.
  • Significant complexity exists in targeting aberrant FGFR signaling effectively.

Conclusions:

  • A deeper understanding of FGFR activation mechanisms is essential.
  • Identifying factors for response and resistance is critical for optimizing FGFR-targeted cancer treatments.
  • Further research is needed to overcome challenges in FGFR-targeted therapy.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56